Institutional Ownership
Aspire Biopharma Hldgs Inc
CUSIP 738920115*W EXP 02/14/203ASBPWQ1 2026
13D / 13G Filings
0
Schedule 13D/13G on record
Beneficial Filers
0
Distinct reporting persons
Largest Stake
—
Max % of class reported
Institutional Holders
29
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
Schedule 13D (activist) & 13G (passive) 5%+ ownership filings
No 13D/13G filings on record yet
Schedule 13D/13G beneficial-ownership filings from 2020–present are ingested from SEC EDGAR. Coverage expands as the backfill and daily crawler run.
Top Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Saba Capital Management, L.P. | 983.6K | $17.9K |
| 2 | Adage Capital Partners Gp, L.L.C. | 1.05M | $17.4K |
| 3 | Linden Advisors LP | 900.0K | $16.9K |
| 4 | Aristeia Capital, L.L.C. | 681.5K | $12.4K |
| 5 | Sculptor Capital LP | 500.0K | $9.1K |
| 6 | Toronto Dominion Bank | 516.3K | $8.8K |
| 7 | Clear Street Group Inc. | 330.7K | $5.5K |
| 8 | D. E. Shaw & Co., Inc. | 200.0K | $3.3K |
| 9 | Wolverine Asset Management LLC | 197.1K | $3.3K |
| 10 | Verition Fund Management LLC | 191.0K | $3.2K |